In order to verify the necessity of TAK1 in the role of USP13 in NAFLD, we adopted the TAK1 inhibtor-5Z-7-Oxozeaenal to inhibit the activation of TAK1. Here, USP13 is linked to metabolic dysfunction-associated steatotic liver disease.